Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kenneth Moch Insider Profile
4 Followers
Kenneth Moch, President & CEO, Director at Chimerix, holds 232.30K shares in Gamida Cell (Ticker: GMDAQ), holds 0.00 shares in Zynerba Pharmaceuticals (Ticker: ZYNE), holds 1.31K shares in Chimerix (Ticker: CMRX).
Kenneth Moch has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
President & CEO, Director
Roles that Kenneth Moch holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Kenneth Moch
Kenneth Moch's Trading History
Chimerix
Mar 17, 2014
President & CEO, Director
Uninformative Sell
474.48K
$1.16K
Zynerba Pharmaceuticals
Oct 11, 2023
―
Uninformative Sell
―
$0.00
Gamida Cell
Feb 02, 2024
―
Uninformative Buy
―
$3.72K
Emisphere Technologies
―
―
―
$0.00
List of latest transactions for each holding click on a transaction to see Kenneth Moch's performance on stock
You May Also Like
Kenneth Moch insider profile FAQ
What is the percentage of profitable transactions made by Kenneth Moch?
The percentage of profitable transactions made by Kenneth Moch is ―.
What is the average return per transaction made by Kenneth Moch?
The average return per transaction made by Kenneth Moch is ―.
What stocks does Kenneth Moch hold?
Kenneth Moch holds: CMRX, ZYNE, GMDAQ, EMIS stocks.
What was Kenneth Moch’s latest transaction?
Kenneth Moch latest transaction was an Uninformative Buy of ―.
What was Kenneth Moch's most profitable transaction?
Kenneth Moch’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Kenneth Moch's role in Chimerix?
Kenneth Moch's role in Chimerix is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.